Adding Dostarlimab Improves Progression-Free Survival in Endometrial Cancer

TUESDAY, April 4, 2023 -- For patients with primary advanced or recurrent endometrial cancer, dostarlimab plus carboplatin-paclitaxel increases progression-free survival versus carboplatin-paclitaxel alone, according to a study published online...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news